Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAL 16.8% Cream DL-PDT for Actinic Keratosis
NCT04085367Phase 3Completed
- Sponsor
- Galderma
- Start
- Sep 2019
- Primary completion
- Mar 2021
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 2
01
Overview
A Phase 3 trial of methyl aminolevulinate in actinic keratosis (AK), sponsored by Galderma. Started Sep 2019; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT04085367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085367.